Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

Project Oncology®

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
While endocrine therapy (ET) and CDK4/6 inhibitors are the standard for treating ER+/HER2- metastatic breast cancer, patients can become resistant to ET. To overcome these resistance mechanisms, the ELEVATE study examines whether combining elacestrant with ET could help address this unmet need. Here to share the preliminary findings from ELEVATE with Dr. Charles Turck is lead study investigator Dr. Hope Rugo. She’s also the Winterhof Distinguished Professor of Breast Oncology and the Director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.